aphilin
koppert deutschland gmbh - aphelinus abdominalis - xppuppen - lebende organismen (insekten) ;
aphelipak
agroline bioprotect - aphelinus abdominalis - xppuppen - lebende organismen (insekten) ;
aphidoletes aphidimyza
andermatt biocontrol suisse ag - aphidoletes aphidimyza - xppuppen - lebende organismen (insekten) ;
aphidoline
omya (schweiz) ag - aphidoletes aphidimyza - xppuppen - lebende organismen (insekten) ;
movento® sc 100
bayer ag - suspensionskonzentrat - 100 g/l spirotetramat - insektizid
mizapak
agroline bioprotect - aphidoletes aphidimyza - xppuppen - lebende organismen (insekten) ;
berryprotect
andermatt biocontrol suisse ag - praon volucre; aphidius ervi; aphidius colemani; aphidius matricariae; aphelinus abdominalis - xppuppen - 41 % ; 17 % ; 17 % ; 17 % ; 8 % ; - lebende organismen (insekten) ;
aphiline veg
omya (schweiz) ag - aphidius ervi; aphidius colemani; aphelinus abdominalis - xaadulte - ; ; ; - lebende organismen (insekten) ;
pokerpak
agroline bioprotect - aphidius colemani; aphidius ervi; aphidoletes aphidimyza; aphelinus abdominalis - xppuppen - 50 % ; 20 % ; 20 % ; 10 % ; - lebende organismen (insekten) ;
phelinun
adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antineoplastische mittel - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.